Accelrys Announces 2005 Product Launch; Open platform technology to enable customers to construct tailored solutions using best-of-breed technology from Accelrys.SAN DIEGO -- Accelrys, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ACCL ACCL American Canadian Caribbean Line ACCL Acceleration ACCL American College of Construction Lawyers ACCL Accreditation Council for Clinical Lipidology (Allied Health Certification Program) ACCL Amway China Co Limited ), today announced the launch of a number of next-generation products across its entire portfolio of software for pharmaceutical, chemical, and materials researchers. Additionally, the company announced its Open Integration Platform, which will integrate Accelrys and SciTegic software in order to enable tailor-made, role-based solutions as well as enhanced intra- and inter-domain productivity. In this launch, Accelrys is introducing over 15 enhanced or new products. Among the highlights are new functionality for molecular biologists, new science for computational chemists, and enhanced platform support. These new offerings put Accelrys on the trajectory to deliver integrated product and service solutions that provide customers with a wide choice of new and improved capabilities. "The launch of this latest suite of products from Accelrys shows our commitment to delivering new science and tools to our clients, extending the broadest & deepest product portfolio in the industry" said Mark J. Emkjer, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Accelrys. "By taking our point-products and identifying toolsets that can enable scientists and engineers in various disciplines, we aim to deliver solutions that address the priority requirements for our clients." Extending Discovery Studio Accelrys continues to invest in its Discovery Studio (DS) line of products for life science research. This launch includes the latest release of DS GCG-a package of over 100 powerful sequence analysis tools for bioinformaticians. Also included is DS MedChem Explorer, a tool for designing and optimizing lead compounds at the desktop that has now been enhanced with new ADME/Tox models and support for Linux. DS ViewerPro, which provides desktop access to tools for generating, sharing, and analyzing high quality molecular information, now includes a 2D viewing option, as well as an automatic field fitting option for easier superimposition In graphics, superimposition is the placement of an image or video on top of an already-existing image or video, usually to add to the overall image effect, but also sometimes to conceal something (such as when a different face is superimposed over the original face in a of molecules. DS Accord for Excel, an Excel spreadsheet that allows display and calculation of chemical information, can now retrieve data from Oracle-based Accord Enterprise Informatics products through a simple-to-use data analysis wizard. Enhanced Linux Offerings QUANTA quan·ta n. Plural of quantum. , Accelrys' leading software environment for X-ray crystallographers also features a Linux port and certification on IBM (International Business Machines Corporation, Armonk, NY, www.ibm.com) The world's largest computer company. IBM's product lines include the S/390 mainframes (zSeries), AS/400 midrange business systems (iSeries), RS/6000 workstations and servers (pSeries), Intel-based servers (xSeries) Thinkpads and IntelliStations running Red Hat Linux Red Hat Linux, assembled by Red Hat, was a popular, "middle-aged" Linux distribution (not as old as Slackware but older than Ubuntu) upon its discontinuation in 2004.[1] Red Hat Linux 1.0 was released on November 3, 1994. . Additionally, a number of new methods and algorithms have been added, including an automated model re-building method that substantially reduces model re-building time. Insight II, a molecular modeling and simulation environment for protein modelers, computational chemists and structural biologists now allows seamless integration between Linux and IRIX A Unix-based operating system from SGI that is used in its computer systems from desktop to supercomputer. It is an enhanced version of Unix System V Release 4. IRIX integrates the X Window system with OpenGL, creating the first real time 3D X environment. . Insight II is also certified and optimized on IBM IntelliStations running Red Hat Linux. New science in Insight II includes a new protein-protein docking program called ZDOCKpro. Improved Chemistry For chemists and screening biologists, Accord Enterprise Informatics (AEI AEI American Enterprise Institute AEI Archive of European Integration AEI Australian Education International AEI Automotive Engineering International AEI Australian Education Index AEI Albert Einstein Institute ) provides a robust solution for storing and managing drug discovery data. AEI now incorporates a new version of the Accord Chemistry Engine, which includes new calculators, Markush support, and enhanced stereochemistry stereochemistry, study of the three-dimensional configuration of the atoms that make up a molecule and the ways in which this arrangement affects the physical and chemical properties of the molecule. support. New for Materials Science Materials Studio (MS) Modeling, Accelrys' suite of modeling and simulation products for computational researchers in chemicals and materials R&D, has a number of important new features and upgrades. New functionality is available for polymer chemists in the form of Blends - which allows calculation of miscibility miscibility (miˈ·s More Information For full details on all the enhancements and new products available, please see http://www.accelrys.com/info/launch/ About Accelrys Accelrys, Inc. (NASDAQ:ACCL) is a leading provider of software for computation, simulation, and the management and mining of scientific data used by biologists, chemists and materials scientists, including nanotechnology researchers, for product design as well as drug discovery and development. Accelrys technology and services are designed to meet the needs of today's leading research organizations. The Company is headquartered in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation). San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. . For more information about Accelrys, visit its website at http://www.accelrys.com/. This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 (the "Act"). Such forward looking statements, including statements regarding the future success of Accelrys products launched in 2005 and of its open integration platform, are subject to risks and uncertainties including, but not limited to, the risk that the platform or products will not be successfully completed or achieve market acceptance, and other risks and uncertainties described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-Q Form 10-Q See 10-Q. . All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys claims the protection of the safe harbor for forward-looking statements contained in the Act, and disclaims any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. |
|
||||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion